Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Jump 15.2% in November: Crecon Report
January 18, 2016
- MSD Renews Call for Reinstating Govt’s HPV Vaccine Promotion after WHO Statement
January 15, 2016
- Ono Files Etelcalcetide for Secondary Hyperparathyroidism in Japan
January 15, 2016
- Ribomic Inks New Agreement with Otsuka on Midkine Aptamer; Otsuka to Decide on In-Licensing by Year-End
January 15, 2016
- INDEE Medical Obtains Exclusive Distribution Rights in Japan for Autologous Epidermis Transplant Kit from Australian Company
January 15, 2016
- Weber Says Takeda Made “Big Decision” to Pull Plug on Metabolic R&D
January 14, 2016
- Iwaki Top Brass to Return Remunerations over Embezzlement Issue
January 14, 2016
- Mundipharma Looks to Double Japan Sales of OTC Isodine Products in 5 Years
January 14, 2016
- Lenvima Filed for RCC Indication in EU: Eisai
January 13, 2016
- Enbrel Biosimilar Meets Equivalence Criteria in Global PIII: Daiichi Sankyo
January 13, 2016
- Takeda Allies with Canada’s enGene to Develop GI Disease Therapies
January 13, 2016
- Takeda, US Biotech NsGene Team Up on Cell Encapsulation Therapies for Parkinson’s
January 12, 2016
- Otsuka Files Leukemia Drug Ponatinib in Japan
January 12, 2016
- Lilly Japan, Torii Link Up to Copromote Psoriasis Drug Ixekizumab
January 12, 2016
- Astellas, Boehringer Extend Copromotion Pact for Micardis
January 8, 2016
- Sanofi Launches Japan PIII on Vaccine for C. Diff Infection
January 8, 2016
- Nippon Shinyaku Files Japan NDA for PAH Drug Selexipag
January 8, 2016
- Toray Enters Field of Nucleic Acid Medicine through Tie-Up with Bonac
January 8, 2016
- Belsomra Most Heavily Pitched Drug in November: Anterio
January 7, 2016
- Novartis, Chugai to Close Out Comarketing Scheme for Femara
January 7, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…